TY - JOUR T1 - Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial JF - Anticancer Research JO - Anticancer Res SP - 6499 LP - 6503 DO - 10.21873/anticanres.14672 VL - 40 IS - 11 AU - MILLY BUWENGE AU - ANNA RITA ALITTO AU - SAVINO CILLA AU - ILARIA CAPOCACCIA AU - ERCOLE MAZZEO AU - EDY IPPOLITO AU - GIOVANNA MANTINI AU - GIAMBATTISTA SIEPE AU - LETIZIA CAVALLINI AU - VINCENZO VALENTINI AU - FRANCESCO DEODATO AU - ALESSIO G. MORGANTI AU - GABRIELLA MACCHIA Y1 - 2020/11/01 UR - http://ar.iiarjournals.org/content/40/11/6499.abstract N2 - Background/Aim: Late toxicity and long-term outcomes of a phase I-II trial on patients with prostate cancer treated with an integrated boost to the dominant intraprostatic lesion (DIL) are reported. Patients and Methods: Patients were treated using intensity-modulated radiotherapy, with a simultaneous integrated boost to the DIL, defined on staging magnetic resonance imaging, delivering 72 Gy in 1.8 Gy/fraction to prostate/seminal vesicles and 80 Gy in 2 Gy/fraction to the DIL. The primary endpoint was acute toxicity and secondary endpoints were late toxicity and biochemical disease-free survival. Results: Forty-four patients were enrolled. The median follow-up was 120 (range=25-150) months. Five-year rates of grade 3 late gastrointestinal and genitourinary toxicity were 2.3% and 4.5%, respectively; only one grade 4 late genitourinary toxicity was recorded. Five-year biochemical relapse-free and overall survival rates were 95.3% and 95.5%, respectively. Conclusion: The treatment was well tolerated and achieved excellent results in terms of outcome in patients with low-intermediate Gleason's score and low risk of nodal metastasis. ER -